Biotech · Public company · Redwood City, CA, US

Bolt Biotherapeutics, Inc.

Ticker BOLT · SEC CIK 0001641281

Track this companyFree. Adds Bolt Biotherapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials30 recruiting or active

Pipeline programs6From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline6

BDC-1001Phase 2 · HER2-positive Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
BDC-1001Phase 2 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
NivolumabPhase 2 · HER2-positive Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
PertuzumabPhase 2 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
BDC-3042Phase 1 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
CemiplimabPhase 1 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerPHASE2 · TERMINATED · started Nov 30, 2023ClinicalTrials.gov NCT05954143 · fetched Nov 12, 2026
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesPHASE1 · TERMINATED · started Oct 11, 2023ClinicalTrials.gov NCT06052852 · fetched Nov 12, 2026
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsPHASE1_PHASE2 · TERMINATED · started Feb 24, 2020ClinicalTrials.gov NCT04278144 · fetched Nov 12, 2026